Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China
Authors' conclusion
GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently. Nevertheless, semaglutide exhibits relatively favourable economic potential across multiple subgroups.
Study context
- Population
- Adults with overweight and obesity without diabetes, China
- Comparison
- Benaglutide, liraglutide, semaglutide, tirzepatide vs lifestyle management
- Outcome
- Incremental cost-effectiveness ratio vs lifestyle management (WTP threshold $37 067.75, 3× per capita gross domestic product (GDP))
- Follow-up
- Lifetime
Methodological detailsMarkov model with network meta-analysis, lifetime horizon, 1-year cycle, Chinese healthcare system perspective, sensitivity and scenario analyses
- Markov model with network meta-analysis
- Lifetime horizon
- 1-year cycle
- Chinese healthcare system perspective
- Sensitivity and scenario analyses
Pooled result
As reported in the abstract
ICER vs lifestyle management
Benaglutide
$227 355.26
Liraglutide
$47 994.81
Semaglutide
$42 818.20
Tirzepatide 10 mg
$72 380.49
Tirzepatide 15 mg
$89 147.19
Further pooled results
Probabilistic sensitivity analysis
- Lifestyle management most likely to be cost-effective under the willingness-to-pay (WTP) threshold
Scenario analysis (severe obesity; first-tier cities)
- Semaglutide the most cost-effective option
Original publication
Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China. Diabetes Obes Metab. Published 4 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →